(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.48%) $79.38
(1.14%) $1.954
(0.86%) $2 330.90
(0.53%) $26.89
(1.37%) $968.00
(0.00%) $0.933
(-0.10%) $11.02
(-0.10%) $0.798
(0.27%) $93.51
-10.87% $ 0.0410
Live Chart Being Loaded With Signals
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia...
Stats | |
---|---|
Volumen de hoy | 61.36M |
Volumen promedio | 6.43M |
Capitalización de mercado | 65.07M |
EPS | $0 ( 2024-02-25 ) |
Próxima fecha de ganancias | ( $0 ) 2024-07-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0315 |
ATR14 | $0.00600 (14.63%) |
Volumen Correlación
Incannex Healthcare Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Incannex Healthcare Ltd Correlación - Moneda/Commodity
Incannex Healthcare Ltd Finanzas
Annual | 2022 |
Ingresos: | $1.01M |
Beneficio Bruto: | $1.01M (100.00 %) |
EPS: | $-0.0130 |
FY | 2022 |
Ingresos: | $1.01M |
Beneficio Bruto: | $1.01M (100.00 %) |
EPS: | $-0.0130 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-6 338.00 (0.00 %) |
EPS: | $-0.00700 |
Financial Reports:
No articles found.
Incannex Healthcare Ltd
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico